Click on a filter below to refine your search. Remove a filter to broaden your search.
Merck says the vaccine covers serotypes responsible for approximately 84% of invasive pneumococcal disease in adults aged 50 or more years.
Zevtera is approved for S. aureus bloodstream infections, acute bacterial skin/skin structure infections and bacterial pneumonia.